

Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study

Authors

Thomas Chalopin,¹ Cyrille Hulin,² Bruno Royer,³ Jean-Noel Bastie,⁴ Arthur Bobin,⁵ Karim Belhadj Merzoug,⁶ Margaret Macro,⁷ Lionel Karlin,⁸ Caroline Jacquet,⁹ Mohamad Mohty,¹⁰ Laurent Frenzel,¹¹ Cécile Sonntag,¹² Jean Fontan,¹³ Sophie Rigau, ¹⁴ Murielle Roussel,¹⁵ Laurence Sanhes,¹⁶ Driss Chaoui,¹⁷ Laure Vincent,¹⁸ Hubert Orfeuvre,¹⁹ Malek Bouketouche,²⁰ Ronan Garlantezec,²¹ Olivier Decaux²² and Aurore Perrot²³

¹Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire (CHU) Tours, Hôpital Bretonneau, Tours; ²Service d'Hématologie, Hôpital Haut Lévêque, Pessac; ³Service d'Hématologie, Hôpital Saint-Louis, Paris; ⁴Hématologie Clinique, CHU Dijon Bourgogne, Dijon; ⁵Service d'Hématologie, Hôpital Poitiers, Poitiers; ⁶Unité Fonctionnelle Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil; ⁷Service d'Hématologie, Hôpital Caen, Caen; ⁸Service d'Hématologie, Hôpital Lyon, Lyon; ⁹CHU de Nancy, Vandoeuvre les Nancy; ¹⁰Sorbonne University, Saint-Anne Hospital (AP-HP), INSERM UMRS-938, Paris; ¹¹Service d'Hématologie, Hôpital Necker, Paris; ¹²Hôpital Hautepierre, Strasbourg; ¹³Service d'Hématologie, Centre Hospitalier Régional Universitaire Jean Minjoz, Besançon; ¹⁴Service

d'Hématologie, Centre Hospitalier de Versailles André Mignot, Le Chesnay; ¹⁵Hématologie Clinique, CHU de Limoges, Hospital Dupuytren, Limoges; ¹⁶Centre Hospitalier Perpignan, Perpignan; ¹⁷Hôpital Victor Dupouy, Argenteuil; ¹⁸Département d'Hématologie Clinique, Hôpital Saint Eloi, CHU de Montpellier; ¹⁹Hôpital de Fleyriat, Bourg en Bresse; ²⁰Centre Hospitalier Saint-Quentin, Saint Quentin; ²¹Santé Publique et Épidémiologie, CHU de Rennes, Rennes; ²²Service d'Hématologie, Hôpital Rennes, Rennes and ²³Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Correspondence:
T. Chalopin - t.chalopin@chu-tours.fr

<https://doi.org/10.3324/haematol.2025.287954>

Received: April 4, 2025.
Accepted: August 20, 2025.
Early view: August 28, 2025.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

Supplementary Table 1 Summary of efficacy according to whether the 2nd- or 3rd-line of treatment included an anti-CD38 mAb

	Not treated with an anti-CD38 mAb (N=962)	Treated with an anti-CD38 mAb (N=822)
Analysis of time-to-next treatment		
Median (95% CI), months	15.9 (14.3-17.7)	29.8 (25.4-33.9)
Time-to-next treatment rates, % (95% CI)		
At 6 months	74.6 (71.9-77.4)	82.1 (79.5-84.8)
At 1 year	58.6 (55.4-61.8)	69.3 (66-72.6)
At 2 years	38.8 (35.5-42.1)	56 (52.1-59.9)
At 3 years	26.4 (23.3-29.5)	44.1 (39.4-48.9)
At 4 years	20.2 (17.2-23.2)	30 (22.2-37.9)
At 5 years	16.2 (13-19.3)	27.3 (18.6-36.1)
Analysis of progression-free survival		
Median (95% CI), months	14.5 (13.5-16.5)	26.3 (22.7-29.7)
Progression-free survival rates, % (95% CI)		
At 6 months	73.1 (70.2-75.9)	78.9 (76.1-81.7)
At 1 year	56.2 (53-59.4)	66.1 (62.7-69.4)
At 2 years	35.1 (31.9-38.3)	52.2 (48.3-56.1)
At 3 years	25.5 (22.5-28.6)	39.3 (34.5-44)
At 4 years	20.1 (17.1-23.1)	25 (18-32)
At 5 years	11.8 (8.1-15.5)	16.7 (2.5-30.8)
Analysis of overall survival		

Median (95% CI), months	46.1 (39.2-54.8)	NR (NR-NR)
Overall survival rates, % (95% CI)		
At 6 months	89 (87.0-91.0)	93.8 (92.2-95.5)
At 1 year	80.7 (78.1-83.3)	84.8 (82.2-87.3)
At 2 years	68.4 (65.3-71.5)	73.5 (69.9-77)
At 3 years	55.9 (52.4-59.4)	63.6 (59.1-68.2)
At 4 years	49.4 (45.7-53.1)	57 (50.8-63.2)
At 5 years	45 (40.9-49.1)	57 (50.8-63.2)

CI, confidence interval; mAb, monoclonal antibody; NR, not reached.